AR035933A1 - Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato. - Google Patents
Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato.Info
- Publication number
- AR035933A1 AR035933A1 ARP020100197A ARP020100197A AR035933A1 AR 035933 A1 AR035933 A1 AR 035933A1 AR P020100197 A ARP020100197 A AR P020100197A AR P020100197 A ARP020100197 A AR P020100197A AR 035933 A1 AR035933 A1 AR 035933A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- represent
- hydroxy
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 title 2
- 239000002131 composite material Substances 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- -1 acyclic nucleoside phosphonate derivative compound Chemical class 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002071 phenylalkoxy group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto derivado de fosfonato nucleósido acíclico representado por la fórmula (1) en la cual ----- representa un enlace simple o enlace doble; R1, R2, R3, R7 y R8 independientemente uno del otro, representan hidrógeno, halógeno, hidroxi, amino, alquilo c1-7, alquenilo C2-6, alquilamino C1-5, aminoalquilo C1-5 o alcoxi C1-5; R4 y R5, independientemente uno del otro, representan hidrógeno o representan alquilo C1-4, opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo que consiste en halógeno (en particular, flúor), alcoxi C1-4, fenoxi, fenilalcoxi C7-10 y aciloxi C2-5, o representan acilo C1-7, arilo C6-12 o carbamoílo opcionalmente sustituido, o representan -(CH2)m-OC(=O)-R6, donde m denota un número entero de 1 a 12 y R6 representa alquilo C1-12, alquenilo C2-7, alcoxi C1-5, alquilamino C1-7, di(alquil C1-7) amino, cicloalquilo C3-6, o heterociclo de 3 a 6 miembros que tienen 1 o 2 heteroátomos seleccionados de un grupo que consiste en nitrógeno y oxígeno; Y representa -O-, -S-, -CH(Z)-, =C(Z)-, -N(Z)-, =N-, -SiH(Z)-, o =Si(Z)-, donde Z representa hidrógeno, hidroxi o halógeno, o representa alquilo C1-7, alcoxi C1-5, alilo, hidroxi-alquilo C1-7, aminoalquilo C1-7 o fenilo; Q representa un grupo que tiene las fórmulas (2), (3), (4) o (5) en las cuales X1, X2, X3 y X4, independientemente uno del otro, representan hidrógeno, amino, hidroxi o halógeno, o representan alquilo C1-7, alcoxi C1-5, alilo, hidroxi-alquilo C1-7, fenilo o fenoxi, cada uno de los cuales se encuentra opcionalmente sustituido por nitro o alcoxi C1-5, o representan ariltio C6-10, que está opcionalmente sustituido por nitro, amino, alquilo C1-6 o alcoxi C1-4 o representan arilamino C6-12, alquilamino C1-7, di(alquil C1-7) amino, cicloalquilamino C3-6 o una estructura (6), en la cual n denota un número entero de 1 o 2; e Y1 representa O, CH2 o N-R (R representa alquilo C1-7 o arilo C6-12); que resulta de utilidad como un agente antiviral (en particular, contra el virus de la hepatitis B). También se divulga el uso, una sal farmacéuticamente aceptable o un estereoisómero del mismo, un proceso para la preparación del mismo, y un compuesto de fosfonato utilizado como intermediario para la preparación del compuesto de fórmula (1) representado por la fórmula (7), en la cual R1, R2, R3, R4, R5, R7, R8 e Y se definen de acuerdo a lo arriba expuesto, y L representa un grupo de salida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20010003087 | 2001-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035933A1 true AR035933A1 (es) | 2004-07-28 |
Family
ID=36241797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100197A AR035933A1 (es) | 2001-01-19 | 2002-01-21 | Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7157448B2 (es) |
| EP (1) | EP1358198B1 (es) |
| JP (1) | JP3959348B2 (es) |
| KR (1) | KR100441638B1 (es) |
| CN (1) | CN100347185C (es) |
| AR (1) | AR035933A1 (es) |
| AT (1) | ATE478887T1 (es) |
| AU (1) | AU2002230230B2 (es) |
| BR (1) | BR0206165A (es) |
| CA (1) | CA2433591C (es) |
| DE (1) | DE60237429D1 (es) |
| DK (1) | DK1358198T3 (es) |
| EG (1) | EG24382A (es) |
| ES (1) | ES2350197T3 (es) |
| MX (1) | MXPA03006001A (es) |
| MY (1) | MY141789A (es) |
| NZ (1) | NZ526632A (es) |
| PL (1) | PL212730B1 (es) |
| PT (1) | PT1358198E (es) |
| RU (1) | RU2266294C2 (es) |
| WO (1) | WO2002057288A1 (es) |
| ZA (1) | ZA200304181B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141789A (en) | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
| US20060079493A1 (en) * | 2001-03-01 | 2006-04-13 | Lawrence Fritz | Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors |
| JP4397691B2 (ja) | 2001-10-30 | 2010-01-13 | コンフォーマ・セラピューティクス・コーポレイション | Ｈｓｐ９０阻害活性を有するプリン類似体 |
| RU2005108601A (ru) * | 2002-09-26 | 2006-01-20 | Эл Джи Лайф Сайенсиз Лтд. (Kr) | (+)-транс-изомеры(1-фосфонометокси-2-алкилциклопропил)метилнуклеозидные производные, способ получения их стереоизомеров и применение указанных соединений в качестве противовирусных средств |
| KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물 |
| KR20050062940A (ko) * | 2003-12-19 | 2005-06-28 | 주식회사 엘지생명과학 | 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법 |
| KR20050062944A (ko) * | 2003-12-19 | 2005-06-28 | 주식회사 엘지생명과학 | 디이소프로필((1-((2-아미노-6-클로로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법 |
| WO2005079812A1 (en) * | 2004-02-17 | 2005-09-01 | Lg Life Sciences Ltd. | Nucleoside phosphonate derivatives useful in the treatment of hiv infections |
| KR101033290B1 (ko) * | 2004-07-02 | 2011-05-09 | 주식회사 엘지생명과학 | 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 |
| US8101745B2 (en) | 2004-12-16 | 2012-01-24 | The Regents Of The University Of California | Lung-targeted drugs |
| EP1869027A4 (en) | 2005-03-30 | 2010-06-23 | Conforma Therapeutics Corp | ALKYNYL-PYRROLOPYRIMIDINES AND CORRESPONDING ANALOGS AS HSP90 INHIBITORS |
| US8434912B2 (en) * | 2006-02-27 | 2013-05-07 | Illumination Management Solutions, Inc. | LED device for wide beam generation |
| EP2942611B1 (en) * | 2006-02-27 | 2022-04-06 | Signify Holding B.V. | An apparatus for use in a street light installation |
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| CL2008000070A1 (es) * | 2007-01-17 | 2008-07-25 | Lg Life Sciences Ltd | Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h |
| NZ608343A (en) | 2007-04-13 | 2014-09-26 | Southern Res Inst | Anti-angiogenic agents and methods of use |
| AU2008254676B2 (en) * | 2007-05-21 | 2012-03-22 | Illumination Management Solutions, Inc. | An improved LED device for wide beam generation and method of making the same |
| MX2011001685A (es) * | 2008-08-14 | 2011-08-17 | Cooper Technologies Co | Dispositivos de led para la generacion de dispersion amplia de haz. |
| US8256919B2 (en) * | 2008-12-03 | 2012-09-04 | Illumination Management Solutions, Inc. | LED replacement lamp and a method of replacing preexisting luminaires with LED lighting assemblies |
| CN102093422B (zh) * | 2009-12-10 | 2015-02-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 无环核苷膦酸酯衍生物及其医药用途 |
| CN102286026B (zh) * | 2010-06-18 | 2014-07-02 | 中国人民解放军军事医学科学院毒物药物研究所 | 无环核苷酸类似物的盐及其晶型和药物组合物 |
| CN103338754A (zh) | 2010-12-10 | 2013-10-02 | 西格玛制药实验有限责任公司 | 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物 |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| CN105246902B (zh) | 2013-03-15 | 2018-05-04 | 加利福尼亚大学董事会 | 无环核苷膦酸二酯 |
| CN104119385B (zh) * | 2014-07-24 | 2017-04-05 | 廖国超 | 核苷类似物的磷酸酯前药及其应用 |
| CN111808136B (zh) | 2014-09-15 | 2024-06-11 | 加利福尼亚大学董事会 | 核苷酸类似物 |
| CN106432330B (zh) * | 2015-08-11 | 2019-02-01 | 天津科伦药物研究有限公司 | Lb80380药物的中间体化合物及其制备方法和用途 |
| EP3875462A1 (en) | 2015-09-15 | 2021-09-08 | The Regents of The University of California | Nucleotide analogs |
| CN106977548A (zh) * | 2016-01-19 | 2017-07-25 | 四川海思科制药有限公司 | 倍司福韦复合物及其制备方法和用途 |
| CN107849074A (zh) * | 2016-01-19 | 2018-03-27 | 四川海思科制药有限公司 | 一种核苷类似物的烷氧烷基酯前药及其应用 |
| KR102623581B1 (ko) | 2016-07-18 | 2024-01-11 | 일동제약(주) | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
| CN108276443A (zh) * | 2017-01-06 | 2018-07-13 | 米文君 | 一种新的化合物及其用途 |
| KR102096144B1 (ko) * | 2017-07-03 | 2020-04-01 | 주식회사 엘지화학 | 포스포네이트 뉴클레오사이드계 b형 간염 치료제 합성용 중간체 화합물의 연속식 제조방법 |
| CN108997429B (zh) * | 2018-07-27 | 2020-10-30 | 广州粤美医药科技有限公司 | 一种制备贝西福韦的方法 |
| CN113735863A (zh) * | 2021-09-29 | 2021-12-03 | 武汉九州钰民医药科技有限公司 | Wee1抑制剂adavosertib的制备工艺 |
| CN113880883A (zh) * | 2021-11-11 | 2022-01-04 | 奥锐特药业股份有限公司 | 核苷类磷酸酯前药的制备方法 |
| CN114560463B (zh) * | 2022-03-23 | 2023-10-20 | 福州大学 | 一种核壳结构的氮掺杂碳壳包裹碳化钼核微米球材料的制备方法 |
| AU2023310177A1 (en) | 2022-07-21 | 2025-03-06 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1494321A (en) * | 1974-08-08 | 1977-12-07 | Ici Ltd | Prostanoic acid derivatives |
| US5688778A (en) * | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
| GB8922076D0 (en) * | 1989-09-28 | 1989-11-15 | Beecham Group Plc | Novel process |
| US5177104A (en) | 1990-04-03 | 1993-01-05 | E. R. Squibb & Sons, Inc. | 6-α-hydroxy derivatives of mevinic acids |
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| DE69116750T2 (de) * | 1990-07-04 | 1996-11-14 | Merrell Dow Pharma | 9-Purinyl-Phosphonsäurederivate |
| DK0481214T3 (da) * | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prolægemidler af phosphonater |
| ES2139588T3 (es) * | 1991-03-05 | 2000-02-16 | Ajinomoto Kk | Derivado de ciclopropano. |
| US5817647A (en) * | 1993-04-01 | 1998-10-06 | Merrell Pharmaceuticals Inc. | Unsaturated acetylene phosphonate derivatives of purines |
| DE69426904T2 (de) * | 1993-06-29 | 2001-10-11 | Mitsubishi Chemical Corp., Tokio/Tokyo | Phosphonat-Nukleotid Ester-Derivate |
| AU690587B2 (en) * | 1993-09-17 | 1998-04-30 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
| WO1995022330A1 (en) | 1994-02-17 | 1995-08-24 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| IT1270008B (it) | 1994-09-23 | 1997-04-16 | Ist Superiore Sanita | Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
| US5877166A (en) * | 1996-04-29 | 1999-03-02 | Sri International | Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| CN1130362C (zh) | 1997-08-15 | 2003-12-10 | 美迪维尔公司 | 核苷类似物,这些化合物作为包括乙型肝炎病毒(hbv)的逆转录病毒的逆转录酶及dna聚合酶抑制剂的抗病毒药 |
| MY141789A (en) * | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
| CA2479037C (en) * | 2002-03-15 | 2010-11-09 | Jiri Zemlicka | 2-amino-9[(2-hydroxymethyl)cyclopropylidenemethyl]purines as antiviral agents |
| RU2005108601A (ru) * | 2002-09-26 | 2006-01-20 | Эл Джи Лайф Сайенсиз Лтд. (Kr) | (+)-транс-изомеры(1-фосфонометокси-2-алкилциклопропил)метилнуклеозидные производные, способ получения их стереоизомеров и применение указанных соединений в качестве противовирусных средств |
-
2002
- 2002-01-16 MY MYPI20020143A patent/MY141789A/en unknown
- 2002-01-18 US US10/450,780 patent/US7157448B2/en not_active Expired - Fee Related
- 2002-01-18 KR KR10-2002-0003051A patent/KR100441638B1/ko not_active Expired - Fee Related
- 2002-01-18 AU AU2002230230A patent/AU2002230230B2/en not_active Ceased
- 2002-01-18 JP JP2002557964A patent/JP3959348B2/ja not_active Expired - Fee Related
- 2002-01-18 PL PL373670A patent/PL212730B1/pl not_active IP Right Cessation
- 2002-01-18 ES ES02711484T patent/ES2350197T3/es not_active Expired - Lifetime
- 2002-01-18 PT PT02711484T patent/PT1358198E/pt unknown
- 2002-01-18 EP EP02711484A patent/EP1358198B1/en not_active Expired - Lifetime
- 2002-01-18 DE DE60237429T patent/DE60237429D1/de not_active Expired - Lifetime
- 2002-01-18 CA CA002433591A patent/CA2433591C/en not_active Expired - Fee Related
- 2002-01-18 RU RU2003125372/04A patent/RU2266294C2/ru not_active IP Right Cessation
- 2002-01-18 MX MXPA03006001A patent/MXPA03006001A/es active IP Right Grant
- 2002-01-18 AT AT02711484T patent/ATE478887T1/de active
- 2002-01-18 BR BR0206165-1A patent/BR0206165A/pt not_active IP Right Cessation
- 2002-01-18 CN CNB028037774A patent/CN100347185C/zh not_active Expired - Lifetime
- 2002-01-18 NZ NZ526632A patent/NZ526632A/en not_active IP Right Cessation
- 2002-01-18 WO PCT/KR2002/000086 patent/WO2002057288A1/en not_active Ceased
- 2002-01-18 DK DK02711484.2T patent/DK1358198T3/da active
- 2002-01-19 EG EG20020063A patent/EG24382A/xx active
- 2002-01-21 AR ARP020100197A patent/AR035933A1/es active IP Right Grant
-
2003
- 2003-05-29 ZA ZA200304181A patent/ZA200304181B/en unknown
-
2006
- 2006-06-20 US US11/455,679 patent/US7605147B2/en not_active Expired - Fee Related
-
2009
- 2009-09-09 US US12/585,229 patent/US7723319B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035933A1 (es) | Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato. | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| AR036046A1 (es) | Inhibidores de la hiv proteasa, composiciones que las contienen y sus usos farmaceuticos | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
| AR034858A1 (es) | Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| AR035812A1 (es) | Compuestos de acrilamida farmaceuticamente efectivos como inhibidores de la enoil-acp reductasa-fabi-; composiciones formuladas con dichos compuestos, metodo para inhibir dicha reductasa , respectivamente, para tratar infecciones bacterianas utilizando dichos compuestos y uso de los compuestos menci | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| AR040474A1 (es) | Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| AR048213A1 (es) | 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| CL2024000581A1 (es) | Compuestos de 6-aminopirazolopirimidina y su uso médico. | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| AR020154A1 (es) | Derivados de glicol de xantinas, composiciones farmaceuticas, uso en la manufactura de medicamentos, metodos de tratamiento y proceso de preparacion | |
| AR035188A1 (es) | Carboxamidas heterociclicas, formulacion farmaceutica, el uso de dichos derivados para preparar medicamentos, agentes antivirales y un metodo in vitro para inhibir una polimerasa de adn viral | |
| PE20220252A1 (es) | Compuestos de pirrol | |
| PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
| AR041405A1 (es) | Derivados de (+) - trans - isomeros de ( 1- fosfonometoxi - 2 alquiciclopropil) metil nucleosido, un procedimiento para la preparacion de esteroisomeros de los mismos y utilizacion de agentes antivirales de los mismos | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| UY28688A1 (es) | Derivados de amida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |